Initiative / Second primary malignancies in thyroid cancer patients

Second primary malignancies in thyroid cancer patients
  1. Home
  2. Initiatives
  3. Second primary malignancies in thyroid cancer patients

Second primary malignancies in thyroid cancer patients

Studies 3
Evaluate the risk of second cancer and leukaemia in patients with papillary or follicular thyroid cancer treated with radioiodine or external beam radiation therapy.

Members

Affiliated Members
Investigators Contacts
  • Dr. Florent de Vathaire
    INSERM (French Institut National de la Santé et de la Recherche Médicale)

General Information

Year created
2003
Types of cohorts
  • Patient/disease cohort
Countries
  • France
  • Italy
  • Sweden
Setting
International
Funding
This study was supported by grants from the European Commission (Concerted action no. FI4P-T98-0078, DG 12-WSMN), the Association pour la Recherche sur le Cancer, the Ligue Nationale Contre le Cancer (Comite ́s de la Marne, des Ardennes et de l’Aude), the Fondation de France (Leg Doris Levy and a thesis fellowship), the Electricité De France, COGEMA, and FRAMA-TOME.
Criteria of cohort's to be included
At the time of publications, the cohorts were the only thyroid cancer cohorts with details on radio iodine adminisration published in Europe
Health topic
  • Cancer
Socio-environmental context
  • NA

Participants

Number of participants

Total
11,007
With harmonized data
11,007

Age range of the samples

Minimum age
2
Maximum age
91

Methodology for harmonization and integration

Strategy of harmonization
Ex-post
Data processing methods
  • Algorithmic
  • Multiple imputation
    • Type of infrastructure
    Data are centrally located
    Integrative data analysis
    • Pooled analyses
    Software
  • SAS
    • Supplementary information
    Rubino C et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003 Nov 3;89(9):1638-44 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394426/

    Number of cohorts

    Total
    6
    With harmonized data
    6
    Will more cohorts be harmonized?
    Number of harmonized variables (max.)
    10

    Access

    Availability of metadata
    Under request
    Availability of individual data
    Under request

    Individual Studies

    Acronym Name Study design Participants Countries
    de Vathaire_Br J Cancer_1997 de Vathaire_Br J Cancer_1997 Patients' cohort 1,771
    Dottorini_J Nucl Med_1995 Dottorini_J Nucl Med_1995 Clinical trial cohort 814
    Hall_Br J Cancer_1991 Hall_Br J Cancer_1991 Clinical trial cohort 1,995